Your English writing platform
Discover LudwigExact(6)
Database URL: http://www.cancerest.org.uk Identifying novel candidate markers/targets is a key challenge in the development of cancer therapies (1).
However, metformin alone frequently fails to maintain glycemic control in the long term (2), and most patients with type 2 diabetes will require additional therapies (1).
The glucagon-like peptide-1 (GLP-1) receptor system has become an attractive target for type 2 diabetes therapies (1– 5).
It is also possible that discontinuing prior therapies 1 week before the study might have aggravated symptoms or led to the onset of new symptoms.
Widespread resistance to most antimalarial drug classes has led to a global adoption of artemisinin-based combination therapies (ACTs) as first-line therapies (1, 2).
Assessment of patient-reported outcomes (PROs), especially treatment satisfaction, is increasingly recognized as important in determining the efficacy of new therapies (1, 2).
Similar(54)
Consequently, novel stimulating approaches recently appeared as promising therapies [1].
About 70% of all breast cancers are ER+ and, thus, potentially sensitive to hormone therapies [1].
We have conducted a Cochrane review of rosacea therapies.1 This article is a distillation of that work.
In vivo bioluminescence imaging (BLI) is a sensitive imaging modality that is rapid and accessible, and may comprise an ideal tool for evaluating antineoplastic therapies [1 ].
Results of this work have direct implications in the future computer-based screening and optimization of inhibitors of DNMT1 and show that computational approaches form part of multidisciplinary efforts to further advance epigenetic therapies [1].
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com